Home/ Supplements/ Niacin/ Nialipin

Nialipin

product on market Tablet or Pill Cardiovascular Research Safety: 60/100
60/100

Review before taking

  • Niacin: 400mg is 11.4× the Tolerable Upper Intake Level (35mg)
  • 100% of ingredients have research evidence
C Label Compliance Grade

What the Evidence Says

✨ AI-generated · Qwen 3.6 · grounded in 1 source · methodology

Niacin is used to manage lipid levels, though research evidence for its efficacy in reducing cardiovascular events is limited. Due to a safety score of 60/100, users should be aware of potential concerns such as skin flushing or liver enzyme elevations. Consult a professional regarding these risks.

AI-generated summary based on research evidence. Not medical advice.

Alerts

Safety Alerts

Niacin: 400mg is 11.4× the Tolerable Upper Intake Level (35mg)

✨ AI-generated · Qwen 3.6 · grounded in 2 sources · methodology

This product received a low safety score because it contains 400mg of Niacin, which is over 11 times the recommended daily upper limit.

Label

Product Label

Label for Nialipin
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Tablet(s)
Serving Size
60
Servings
Vitamin
Product Type
100%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

400 mg (2500% DV)
Exceeds UL by 11.4× (UL: 35 mg) 196 studies (A:5, B:63)

Other Ingredients

Microcrystalline Cellulose Hydroxypropyl Methylcellulose Stearic Acid L-Leucine Silicon Dioxide Ethylcellulose Food Glaze
Claims

Label Claims — Verification

Unverified Nutrient
Unverified All Other
Unverified Structure/Function
Info

Product Information

Directions for Use

Hypersensitive individuals are advised to start with one tablet prior to increasing dosage.

Directions Take one tablet daily, or as directed by a physician.

Warnings & Precautions

Do not cut tablets in half.

Do not take niacin unless recommended by and taken under the supervision of a physician if you have any of the following conditions: gallbladder disease, gout, arterial bleeding, glaucoma, diabetes, impaired liver function, peptic ulcer, or if you are pregnant or lactating.

Formulation Notes

NIALIPIN is well tolerated by sensitive individuals.

400 mg Sustained-Release Niacin

Gluten free, Casein free

Each sustained-release tablet is designed to release niacin over a period of 6 to 8 hours.

Additional Information

Ecological Formulas

Metadata

Product Details

UPC / SKU6 96859 13163 9
DSLD Entry Date2023-12-14
Product TypeVitamin
FormTablet or Pill
BrandCardiovascular Research
DSLD ID304416
Data Updated2026-04-11
Research

Research Evidence

241
Research Sources
55
Avg Quality
113
Meta Analysis
75
Systematic Review
32
Rct
11
Clinical Trial
3
Other
3
Regulatory Source
1
Cochrane Review
1
Narrative Review
1
Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017 PubMed DOI
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013 PubMed DOI
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014 PubMed DOI
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024 PubMed DOI
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010 PubMed DOI
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010 PubMed DOI
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019 PubMed DOI
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016 PubMed DOI
View all evidence for Niacin →
Compare

Similar Products

Rezistaf
LifeLink · Tablet or Pill
100
Coenzymated B-3 25 mg
Source Naturals · Tablet or Pill
100
Vitamin B Complex
Simply Supplements · Tablet or Pill
100
Test X180 Boost
Force Factor · Tablet or Pill
100
8-Hour Alert
MHP Maximum Human Performance · Tablet or Pill
100
View all Niacin products →
Niacin research Best Niacin All Niacin products More from Cardiovascular Research View on NIH DSLD →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.